Catalyst sues FDA over 'capricious' approval for rival by Eric Sagonowsky Wednesday, June 12, 2019 Even after a pricing outcry, Catalyst isn't shying away from controversy. It's suing the FDA for approving a potential rival to its $375,000 Firdapse.
Catalyst's $375K Firdapse could get off-label competition by Eric Sagonowsky Tuesday, May 7, 2019 Jacobus scrored an FDA nod for a drug that could provide some off-label competition for Catalyst's controversial Firdapse.
Patient group urges BIO to boot Catalyst over $375K Firdapse price by Eric Sagonowsky Thursday, March 7, 2019 Nonprofit Patients for Affordable Drugs is getting involved in the Catalyst situation, which they argue is a clear example of price gouging.
Sanders asks FDA to sanction unapproved copies of $375K Firdapse by Angus Liu Thursday, February 28, 2019 Sen. Bernie Sanders wants to circumvent Catalyst Pharma's monopoly on the pricey rare disease drug, but that could be a stretch under current law.
Catalyst defends Firdapse’s $375K sticker against Sanders' ire by Angus Liu Friday, February 22, 2019 To justify its price on Firdapse, a tweaked version of a drug previously given to patients for free, Catalyst used the familiar R&D spending argument.
Catalyst confirms Firdapse's $300,000-plus net price by Arlene Weintraub Tuesday, February 12, 2019 Catalyst is unfazed by a letter from Sen. Bernie Sanders demanding that it justify the cost of its rare-disease drug Firdapse, confirmed at $300K after discounts.
Catalyst's long-delayed Firdapse snags FDA nod by Carly Helfand Thursday, November 29, 2018 It took a breakthrough designation, orphan drug status, a Refuse to File letter and some extra trials, but Catalyst has won an FDA nod for Firdapse.
